Doll, Corinne

Radiation Oncology

Clinical Professor

Biography

Dr. Corinne Doll is a Clinical Professor in the Department of Oncology and Senior Radiation Oncologist at Tom Baker Cancer Centre. Dr. Doll is Deputy Medical Director at Tom Baker Cancer Centre and Deputy Clinical Department Head, Department of Oncology, Calgary Zone.  In addition, she is Clinical Leader, Brachytherapy and Leader of Translational Research, Division of Radiation Oncology. In terms of local educational roles, Dr. Doll is Chair of the Competency By Design Committee and Assistant Program Director, Radiation Oncology Residency Training Program.  National roles include Co-Chair of the Cervical Cancer Working Group of the Canadian Clinical Trials Group, and President-Elect of the Canadian Association of Radiation Oncology.  She is Special Expert of the National Cancer Institute Gynecologic Cancer Steering Committee.  Her clinical practice and research interests are in Gynecology and Gastrointestinal malignancies.

Area of Focus

Summary of Research

Key Publications:

  1. Doll CM, Moughan J, Klimowicz A, Ho CK, Kornaga E, Lees Miller SP, Ajani J, Crane CH, Kachnic LA, Okawara GS, Berk L, Roof K, Becker M, Grisel D, Ellis R, Sperduto P, Marsa G, Guha C. Magliocco A. Significance of co-expression of epidermal growth factor receptor and Ki67 on clinical outcome in patients with anal cancer treated with chemoradiotherapy: An analysis of NRG oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017;97(3):554-562.
  2. Ho CK, Kornaga E, Kilmowica A, Enwere E, Dean M, Bebb G, Phan T, Ghatage P, Magliocco A, Lees- Miller SP, Doll CM. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol. 2017 Apr;145(1):176-184.
  3. Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, Koebel M, Ghatage P, Magliocco AM, Lees-Miller SP, Doll CM. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017 Apr;30(4):577-586.
  4. Arjumand W, Merry CD, Wang C, Saba E, McIntrye JB, Gang S, Kornaga E, Ghatage P, Doll CM, Lees- Miller SP. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget. 2016;7(50):82424-82439.
  5. McIntyre JB, Wu J, Phan T, Craighead PS, Lees-Miller S, Kobel M, Ghatage P, Magliocco AM, Doll CM. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128(3):409-14.

Area Of Focus

Summary Of Research

Key Publications:

  1. Doll CM, Moughan J, Klimowicz A, Ho CK, Kornaga E, Lees Miller SP, Ajani J, Crane CH, Kachnic LA, Okawara GS, Berk L, Roof K, Becker M, Grisel D, Ellis R, Sperduto P, Marsa G, Guha C. Magliocco A. Significance of co-expression of epidermal growth factor receptor and Ki67 on clinical outcome in patients with anal cancer treated with chemoradiotherapy: An analysis of NRG oncology RTOG 9811. Int J Radiat Oncol Biol Phys. 2017;97(3):554-562.
  2. Ho CK, Kornaga E, Kilmowica A, Enwere E, Dean M, Bebb G, Phan T, Ghatage P, Magliocco A, Lees- Miller SP, Doll CM. Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy. Gynecol Oncol. 2017 Apr;145(1):176-184.
  3. Enwere EK, Kornaga EN, Dean M, Koulis TA, Phan T, Kalantarian M, Koebel M, Ghatage P, Magliocco AM, Lees-Miller SP, Doll CM. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017 Apr;30(4):577-586.
  4. Arjumand W, Merry CD, Wang C, Saba E, McIntrye JB, Gang S, Kornaga E, Ghatage P, Doll CM, Lees- Miller SP. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells. Oncotarget. 2016;7(50):82424-82439.
  5. McIntyre JB, Wu J, Phan T, Craighead PS, Lees-Miller S, Kobel M, Ghatage P, Magliocco AM, Doll CM. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2013;128(3):409-14.